Navigation Links
Cholesterol and Cancer: Answers and Some New Questions
Date:11/4/2009

• Study shows low cholesterol as a symptom of cancer rather than a cause. • Possible benefit of higher HDL and cancer risk. • Lower cholesterol may lower risk of high-grade prostate cancer.

Philadelphia, PA (Vocus) November 4, 2009 -- The American Association for Cancer Research hosted a press briefing on this study on Tuesday, Nov. 3, 2009, at 11:30 a.m. ET. A recording of the teleconference and PDFs of the studies and accompanying editorial are available at the bottom of this page.

A pair of studies in Cancer Epidemiology, Biomarkers & Prevention lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer.

Demetrius Albanes, M.D., a senior investigator at the National Cancer Institute, said early studies suggested that low cholesterol could increase the risk of certain types of cancer.

"Our study affirms that lower total cholesterol may be caused by undiagnosed cancer. In terms of public health message, we found that higher levels of ‘good cholesterol' (HDL) seem to be protective for all cancers, which is in line with recommendations for cardiovascular health," said Albanes.

The researchers observed 29,093 men from the Alpha-Tocopheral, Beta-Carotene Cancer Prevention Study cohort for 18 years, making it the largest and longest study of its kind. In that follow-up period, they noted 7,545 cancer cases. Low total cholesterol blood levels were associated with an 18 percent higher risk of cancer overall, similar to the increases seen in previous studies, but this risk disappeared when the researchers excluded cases that occurred in the early years after the original blood draw.

This finding suggests that the low total cholesterol levels did not cause cancer, but rather were the result of underlying cancer, said Albanes. Higher levels of HDL cholesterol were associated with a 14 percent decreased risk of cancer even after excluding nine years of early cases.

In an accompanying study that looked specifically at risk for high-grade prostate cancer, Elizabeth Platz, Sc.D., M.P.H., associate professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and co-director of the Cancer Prevention and Control Program at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University, found a link between low cholesterol and decreased risk of high-grade prostate cancer among 5,586 men older than 55 years.

Specifically, if men had total cholesterol of less than 200 mg/dL they had a 59 percent reduced risk of high-grade prostate cancer, defined as a Gleason score eight to 10. No association was seen for prostate cancer overall or for prostate cancer with a lower Gleason score. Platz said that the study supports another benefit of keeping cholesterol low among men in this age group.

"High-grade prostate cancer is less common than prostate cancer overall, but it is a subset of prostate cancer that is more likely to progress," said Platz.

Discussion of the benefits of lower cholesterol inevitably leads to the discussion of the role of statins, which have produced one of the great public health success stories of the past few decades as cholesterol and, subsequently, heart disease rates have both fallen. Statins have been enormous money makers for their industry manufacturers and with two already off patent, and the largest seller, Lipitor scheduled to go off patent next year, researchers did leave open the possibility that industry leaders may seek a new indication for these blockbuster drugs.

"Until there is evidence from randomized trials, men should not take statins in order to prevent high-grade prostate cancer," said Eric Jacobs, Ph.D., strategic director of pharmacoepidemiology at the American Cancer Society. Jacobs, who wrote an accompanying editorial in the Cancer Epidemiology, Biomarkers & Prevention issue. He said a randomized trial among men without prostate cancer would need to be very large and might not be feasible.

"One possibility, however, would be a randomized trial among early stage prostate cancer patients opting for surveillance rather than immediate treatment, to see if statins could lower risk of prostate cancer progression," Jacobs said.

The AACR hosted a press briefing on this research on Tuesday, Nov. 3, 2009.

The following experts participated in this press briefing:

Timothy Rebbeck, Ph.D.
Associate Professor of Epidemiology
University of Pennsylvania
Editor-in-Chief
Cancer Epidemiology, Biomarkers & Prevention

Elizabeth Platz, Sc.D., M.P.H.
Co-Director, Cancer Prevention and Control Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University

Demetrius Albanes, M.D.
Senior Investigator
National Cancer Institute

Eric Jacobs, Ph.D.
Strategic Director, Pharmacoepidemiology
American Cancer Society

Additional Resources:

Listen to a recording of the teleconference

Read the full studies and accompanying editorial:

Platz et al. Cholesterol and High Grade Prostate Cancer
Albanes et al. Cholesterol and Cancer Risk
Editorial: Answers and Some New Questions

Subscribe to the AACR RSS News Feed
Subscribe to the Cancer Epidemiology, Biomarkers & Prevention RSS Feed

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 30,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowship and career development awards. The AACR Annual Meeting attracts more than 16,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.

###

Read the full story at http://www.prweb.com/releases/cholestrol/11/prweb3160704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Low Cholesterol May Help Prevent Cancer
2. Researchers identify the 3 killer indicators that are even worse than high cholesterol
3. Household Chemicals May Affect Cholesterol Levels
4. Cholesterol Drugs May Help Prevent Flu Deaths
5. Cholesterol-lowering medicines may be effective against cancer
6. Emerging Evidence Shows Strawberries Can Help Lower Cholesterol
7. Use of statins favors the wealthy, creating new social disparities in cholesterol
8. Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol
9. Combo Therapies to Lower Cholesterol Dont Work
10. Video: New Insights Link Low HDL-Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
11. LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cholesterol and Cancer: Answers and Some New Questions
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... technology, welcomes you to stop by for a visit this week at HIMSS ... clinicians and executives from around the globe. Sensogram will be featured in the ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Johns Hopkins All ... education building. A topping out ceremony on Friday marked the halfway point of construction ... to open in Fall 2018, will serve as a center for innovation aimed at ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain ... is being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as ... nursing department in early 2016. After a nation-wide search, she was selected to head ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
(Date:2/18/2017)... Beverly Hills, California (PRWEB) , ... February 17, ... ... 273-3007, info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon ... reduce subcutaneous fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Fla. , Feb. 20, 2017 Seal ... its health IT solution for mobile device management and ... 2017 HIMSS Conference and Exhibition in Orlando, ... #4444. Mobile devices have become commonplace in ... comes a new set of concerns, including the disinfection ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
(Date:2/19/2017)... 2017   AC Group Inc. , a leading ... vendors in the PMS/EHR healthcare marketplace, will exhibit the ... to succeed in this ecosystem at HIMSS,17. ... obtained from over 200 ACOs, compared and analyzed an ... companies that are providing different pieces of Population Health ...
Breaking Medicine Technology: